CoChat
Sign Up
Cited by 649Lipoproteins and Cardiovascular HealthChronic Kidney Disease and DiabetesDialysis and Renal Disease Management

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

Wanner, Christoph, the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, Tonelli, Marcello·2014·Kidney International
DOI 10.1038/ki.2014.31
Open this paper in CoChat — free account

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines on lipid management for all adults and children with chronic kidney disease (CKD). Thirteen recommendations were obtained from the available evidence outlining a three-step management including assessment in all, treatment in many, and follow-up measurements in few. A key element is the recommendation of statin or statin/ezetimibe treatment in adults aged ⩾50 years with estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m(2) but not treated with chronic dialysis or kidney transplantation. In dialysis patients, the magnitude of any relative reduction in risk appears to be substantially smaller than in earlier stages of CKD and initiation of statin treatment is not recommended for most prevalent hemodialysis patients. In the past, clinical practice guidelines suggested the use of targets for LDL cholesterol, which require repeated measurements. Treatment escalation with higher doses of statin would be a consequence when LDL cholesterol targets are not met. The KDIGO Work Group did not recommend this strategy because higher doses of statins have not been proven to be safe in the setting of CKD. Since LDL cholesterol levels do not necessarily suggest the need to increase statin doses, follow-up measurement of lipid levels is not recommended.

Overview

Integrity signals

Registry

Crossref · 10.1038/ki.2014.31

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 0 references

Research works printed but not linked: 38

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group, 2013, KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease, Kidney Int Suppl, 3, 259
  2. Uhlig, 2006, Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 70, 2058, 10.1038/sj.ki.5001875 · DOI
  3. National Kidney Foundation, 2003, K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease, Am J Kidney Dis, 41, S1
  4. Grundy, 2006, Diabetes and coronary risk equivalency: what does it mean?, Diabetes Care, 29, 457, 10.2337/diacare.29.02.06.dc05-1904 · DOI
  5. Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4 · DOI · Paper page
  6. Chiang, 2005, Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients, Blood Purif, 23, 134, 10.1159/000083529 · DOI
  7. Coresh, 1998, Epidemiology of cardiovascular risk factors in chronic renal disease, J Am Soc Nephrol, 9, S24
  8. Iseki, 2002, Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients, Kidney Int, 61, 1887, 10.1046/j.1523-1755.2002.00324.x · DOI
  9. Lowrie, 1990, Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities, Am J Kidney Dis, 15, 458, 10.1016/S0272-6386(12)70364-5 · DOI
  10. Krane, 2009, Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus, Am J Kidney Dis, 54, 902, 10.1053/j.ajkd.2009.06.029 · DOI
  11. Liu, 2004, Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition, J Am Med Assoc, 291, 451, 10.1001/jama.291.4.451 · DOI
  12. Tonelli, 2013, Association between LDL-C and risk of myocardial infarction in CKD, J Am Soc Nephrol, 24, 979, 10.1681/ASN.2012080870 · DOI
  13. Kasiske, 1998, Hyperlipidemia in patients with chronic renal disease, Am J Kidney Dis, 32, S142, 10.1053/ajkd.1998.v32.pm9820472 · DOI
  14. Bachorik, 1995, National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement, Clin Chem, 41, 1414, 10.1093/clinchem/41.10.1414 · DOI
  15. Stein, 1995, National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement, Clin Chem, 41, 1421, 10.1093/clinchem/41.10.1421 · DOI
  16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), J Am Med Assoc, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  17. Kilpatrick, 2007, Association between serum lipids and survival in hemodialysis patients and impact of race, J Am Soc Nephrol, 18, 293, 10.1681/ASN.2006070795 · DOI
  18. Glasziou, 2008, Monitoring cholesterol levels: measurement error or true change?, Ann Intern Med, 148, 656, 10.7326/0003-4819-148-9-200805060-00005 · DOI
  19. Takahashi, 2010, Lipid re-screening: what is the best measure and interval?, Heart, 96, 448, 10.1136/hrt.2009.172619 · DOI
  20. Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3 · DOI · Paper page
  21. Palmer, 2012, Benefits and harms of statin therapy for persons With chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 157, 263, 10.7326/0003-4819-157-4-201208210-00007 · DOI · Paper page
  22. Tonelli, 2006, Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial, BMJ, 332, 1426, 10.1136/bmj.38814.566019.2F · DOI
  23. Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545 · DOI · Paper page
  24. Marz, 2011, Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis, Clin J Am Soc Nephrol, 6, 1316, 10.2215/CJN.09121010 · DOI
  25. Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0 · DOI · Paper page
  26. Saland, 2002, Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management, Curr Opin Pediatr, 14, 197, 10.1097/00008480-200204000-00009 · DOI
  27. Saland, 2007, Lipoprotein metabolism in chronic renal insufficiency, Pediatr Nephrol, 22, 1095, 10.1007/s00467-007-0467-5 · DOI
  28. Strong, 1999, Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study, JAMA, 281, 727, 10.1001/jama.281.8.727 · DOI
  29. National Kidney Foundation, 2009, KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update, Am J Kidney Dis, 53, S1, 10.1053/j.ajkd.2008.11.017 · DOI
  30. Coleman, 1996, Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood, Pediatr Nephrol, 10, 171, 10.1007/BF00862065 · DOI
  31. Garcia-de-la-Puente, 2009, Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders, Pediatr Nephrol, 24, 1205, 10.1007/s00467-009-1128-7 · DOI
  32. Sanjad, 1997, Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy, J Pediatr, 130, 470, 10.1016/S0022-3476(97)70213-0 · DOI
  33. Yoshimura, 1992, The effects of pravastatin on hyperlipidemia in renal transplant recipients, Transplantation, 53, 94, 10.1097/00007890-199201000-00018 · DOI
  34. Zhao, 2012, New fibrate use and acute renal outcomes in elderly adults a population-based study, Ann Intern Med, 156, 560, 10.7326/0003-4819-156-8-201204170-00401 · DOI · Paper page
  35. Cerkauskiene, 2003, Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephritic syndrome], Medicina, 39, 82
  36. Chongviriyaphan, 1999, Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephritic syndrome, J Med Assoc Thai, 82, S122
  37. Goren, 1991, Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy, Pediatrics, 88, 265, 10.1542/peds.88.2.265 · DOI
  38. Hogg, 2006, Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group, Clin J Am Soc Nephrol, 1, 467, 10.2215/CJN.01020905 · DOI

Cited by

Sorted by citations

Items 501–570 of 570

Metadata

Authors
Wanner, C., the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, & Tonelli, M.
Affiliations
  • University of Würzburg (DE)
  • University of Alberta (CA)
Corresponding author
Wanner, Christoph
ORCID
Venue
Kidney International
Publisher
Elsevier BV
Published
2014-06
Volume
85
Issue
6
Pages
1303-1309
ISSN
0085-2538 (ISSN-L)
DOI
10.1038/ki.2014.31
OpenAlex
W1978239396
Cited by
649
References
0
Citations by year
2026: 41 · 2025: 65 · 2024: 65 · 2023: 77 · 2022: 68 · 2021: 61 · 2020: 58 · 2019: 57 · 2018: 41 · 2017: 35 · 2016: 33 · 2015: 31 · 2014: 15
FWCI
37.66
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Kidney International (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Keywords
lipid control, chronic kidney disease, statins, ezetimibe, LDL cholesterol targets, statin dose escalation, hemodialysis, estimated glomerular filtration rate, cardiovascular risk reduction
MeSH terms
Adolescent, Adult, Age Factors, Hypolipidemic Agents, Child, Renal Dialysis, Humans, Lipids, Middle Aged, Nephrology, Risk Factors, Biomarkers, Treatment Outcome, Evidence-Based Medicine, Dyslipidemias, Renal Insufficiency, Chronic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review